Recent studies have also provided evidences of the positive impact of anti-CSPG4 mAb in improving the efficacy of anti-cancer drugs in glioblastoma and melanoma pre-clinical models, indirectly associating the CSPG4 expression with multidrug resistance in these tumor histotypes [58, 102, 103]. Here, CSPG4 is linked to neoplasm.